DBV Submits BLA to FDA for VIASKIN Peanut Patch in Children 4-7, Requests Priority Review
DBVT sits 28% above its 52-week low of $9.13.
Summary
DBV Technologies submitted its BLA to the FDA for the VIASKIN Peanut Patch in children 4-7 years old, backed by positive Phase 3 VITESSE data, and requested Priority Review.
Key Events · Product Development and Regulatory · DBVT
-
BLA Submitted to FDA
On September 29, 2026, a Biologics License Application was submitted for the VIASKIN Peanut Patch in children aged 4-7 years.
-
Priority Review Requested
A Priority Review has been requested, which would shorten the FDA review timeline to approximately six months if granted.
-
Phase 3 VITESSE Data Supports Filing
The BLA is supported by positive results from the VITESSE Phase 3 trial, the largest immunotherapy trial in this population with 654 children across 86 sites.
-
Breakthrough Therapy Designation
The FDA previously granted Breakthrough Therapy Designation to the VIASKIN Peanut Patch, underscoring the unmet need.
Analysis · DBVT · Life Sciences
A pivotal regulatory milestone has been reached: DBV Technologies has submitted its Biologics License Application to the FDA for the VIASKIN Peanut Patch in children aged 4-7 years, supported by positive Phase 3 VITESSE trial results. The company has requested Priority Review, which, if granted, would shorten the FDA review timeline to approximately six months. This matters because DBV has been burning cash rapidly and had previously delayed its BLA submission. Approval would transform DBV from a clinical-stage company into a commercial organization with a first-to-market non-invasive peanut allergy treatment for this age group.
How filings like this one have moved
In the 30 days to Oct 18, 2026, 37.5% of the 937 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DBVT was trading at $11.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $719.4M. The 52-week trading range was $9.13 to $26.19. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.